Reykjavík

Reykjavík has emerged as a life sciences hub, leveraging its and world-class healthcare infrastructure to drive biotechnology and pharmaceutical breakthroughs.

The city is globally recognized for its leadership in genomics and precision medicine, spearheaded by pioneers like deCODE genetics.

In the pharmaceutical sector, Reykjavík is a powerhouse for biosimilars development and generic drug manufacturing, anchored by industry leaders such as Alvotech and Teva (Actavis).

The ecosystem thrives on a "triple helix" of collaboration between academic research institutions like the University of Iceland and the National University Hospital, fostering high-impact healthcare innovation.

Beyond drug discovery, the region is a burgeoning center for medical device technology and digital health solutions, particularly in orthopedic bracing and AI-driven diagnostics.

Strategic investments in biotechnology further distinguish the city, as startups utilize marine resources for advanced wound care and bioactive compounds.

With a strong emphasis on clinical trials and sustainable R&D, the Reykjavík Science City initiative provides a state-of-the-art environment for global biotech companies to scale.

This compact yet robust ecosystem offers unparalleled access to integrated health data, making it an essential destination for international investors seeking the next frontier in biomedical engineering and life science commercialization.